Enlightening light chain deposition disease

Abstract

In this issue of Blood, Sayed et al report on a series of 53 patients with light chain (LC) deposition disease (LCDD) prospectively followed for a median of 6.2 years, showing divergent outcomes in patients who achieve a very good partial response (VGPR) or complete response (CR) compared with those who do not (see figure, panel A). Even patients with advanced chronic kidney disease (CKD) benefited from a deep clonal response.